Condition: Relapsed/Refractory Follicular Lymphoma · Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) · Sponsor: Regeneron Pharmaceuticals
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called "relapsed"), or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL). This study will be made up of two parts (Part 1 not randomized, Part 2 randomized - controlled). The aim of Part 1 of the study is to see how safe and tolerable the study drug is when used in combination with lenalidomide, in participants with FL or MZL, and to determine the dose of the study drug to be used in Part 2 of this study. This combination is considered "first-in-human" as it has not been tested as a combination treatment in humans before. The aim of Part 2, of the study is to assess how well the combination of the study drug and lenalidomide works compared to the combination of rituximab (called "the comparator drug") and lenalidomide. The combination of comparator drug and lenalidomide is the current standard-of-care treatment for relapsed/refractory FL and/or MZL. Standard-of-care means the usual medication expected and used when receiving treatment for a condition. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug in combination with lenalidomide * How much st…
This description comes directly from the study's public registry record.
Clinical Trials Administrator · 844-734-6643 · clinicaltrials@regeneron.com
Always discuss trial participation with your own doctor first.
| David Geffen School of Medicine at UCLA | Los Angeles, California, United States | Recruiting |
| Boca Raton Clinical Research (BRCR) Global | Plantation, Florida, United States | Recruiting |
| Indiana University and Comprehensive Cancer Center | Indianapolis, Indiana, United States | Recruiting |
| Hattiesburg Clinic | Hattiesburg, Mississippi, United States | Recruiting |
| Dartmouth Cancer Center | Lebanon, New Hampshire, United States | Recruiting |
| Stony Brook University Hospital | Stony Brook, New York, United States | Recruiting |
| Clinical Research Alliance Inc | Westbury, New York, United States | Withdrawn |
| Prohealth Care Inc | Waukesha, Wisconsin, United States | Recruiting |
| Liverpool Hospital | Liverpool, New South Wales, Australia | Recruiting |
| Calvary Mater Newcastle | Waratah, New South Wales, Australia | Recruiting |
| Pindara Private Hospital | Benowa, Queensland, Australia | Recruiting |
| Royal Hobart Hospital | Hobart, Tasmania, Australia | Recruiting |
+ 157 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06149286